Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Eli Lilly and Co
LLY
Healthcare
Biotechnology
Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant...
, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. It is also developing oral small molecule inhibitor of a4ß7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NYSE:LLY)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Nov 18, 2024 9:45pm
Lilly's muvalaplin lowered lipoprotein(a) levels in adults w
Just In: $LLY Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested doseLilly's muvalaplin lowered lipoprotein(a
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Nov 17, 2024 7:01am
Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Yea
BREAKING NEWS: $LLY Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Years From Now2024-11-17 06:42:00 ET Tesla (NASDAQ: TSLA) is back. Shares of the electric vehicle (EV) maker plunged as
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Oct 30, 2024 7:00pm
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical
News; $LLY A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years2024-10-30 04:45:00 ET For the past couple of years, two of the biggest themes
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 02, 2024 7:30am
New Press Release - Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials
Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale global access to clinical supply for Lilly's growing pipeline Opening in late 2027, the facility will increase Lilly's total capital commitment in the United States to more...
read article.
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Sep 28, 2024 5:30am
Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever
JUST IN: $LLY Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever2024-09-28 05:15:00 ET In the stock market, ups and downs are inevitable. But long-term investors shouldn't get wrapped up
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 25, 2024 6:45am
New Press Release - New data show Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis
Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority of ADvocate 1 and 2 responders Nearly 87 percent of patients taking EBGLYSS did not require either high-potency topical corticosteroids or systemic treatments during the three-year...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 24, 2024 6:00am
New Press Release - Lilly's Kisunla(TM) (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease
Japan is the second major market where Kisunla has received approvalKisunla was first approved in the United States in July 2024INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 13, 2024 4:08pm
New Press Release - FDA Approves Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicalsPatients treated with EBGLYSS experienced significant skin clearance as early as four weeks and meaningful itch relief as early as two weeksEBGLYSS delivers long...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 12, 2024 5:30am
New Press Release - Lilly expands manufacturing footprint in Ireland with $1.8 billion investment
Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facilityNew investment will enhance global medicine production, benefiting millions of patients worldwideINDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 10, 2024 11:57am
New Press Release - With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes
Detailed results were published in The Lancet and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024INDIANAPOLIS, Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 10, 2024 11:19am
New Press Release - Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes
In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7% Detailed results were published in The New England Journal of Medicine and simultaneously presented at the European Association for the Study of Diabetes (EASD...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 09, 2024 6:45am
New Press Release - Lilly appoints Lucas Montarce as executive vice president and chief financial officer
INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately.Since joining Lilly in 2001...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 05, 2024 6:45am
New Press Release - In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin
In the phase 3 study, QWINT-1, efsitora was administered via four fixed doses once weekly in a single-use autoinjector in people with type 2 diabetes using basal insulin for the first timeIn a second phase 3 study, QWINT-3, efsitora also delivered non-inferior A1C reduction compared to daily...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 04, 2024 6:00am
New Press Release - Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in AfricaINDIANAPOLIS and CAIRO, Sept. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and...
read article.
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 30, 2024 4:33pm
Think Eli Lilly Stock Has Peaked? These 10 Words From the CE
News; $LLY Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind2024-08-30 07:45:00 ET Eli Lilly (NYSE: LLY) stock is up a mammoth 770% in five years. It is trading at new
...more
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
A potential breakthrough in spinal cord and optic nerve injury treatment
Learn How this Company is Disrupting Point-of-Care Testing
Why Dozens of Pro Athletes are Paying Attention to this Product
Debt-Free Cannabis Company Set for Next Stage of Growth
Growth Rocket 2025 – Why dynaCERT is in the Spotlight